Drug agency Recommends Lower Dose of Ambien for Women

Ambien was taken for sleep in American’s for almost 20 years. However, FDA- food and drug administration got complaints that taking that drug made them drowsy the next morning and sometimes led to accidents.

After test on drowsiness risk on driving, the agency said on Thursday that woman should take half the drug.
This applies to the drugs containing Zolpidem. Half dose ensures that less drug remains in the blood and people can drive in the morning.

There is an increased usage of these sleeping pills due to the fast life. As per IMS which a healthcare and technology company, it says that in 2011 there were almost 60 million prescriptions, which was 20% then 2006 and 40 million were for products that was having Zolpidem.

The recommendation was mainly based for women because the mobilization takes longer in them as compared to men. Almost 10% to 15% of women will have the drug in their blood after 8 hours and compared to only 3% men, as said by Dr. Robert Temple, Officer, Center for Drug Evaluation and Research.

There were many reports in regards to problems caused after the use of sleeping pills, and doctors have questioned why it took time for the agency to act so late. The effects are driving in sleep, eating, texting having sex and no memory of the same in the morning, these are all well known.

As said by Daniel Carlat, Associate Clinical professor, Psychiatry, Tufts University, “the agency is behind to pass the recommendation as the doctors are well aware of the conditions like this. This will be good as the patients will ask proper dose.”

Agency said that there were 700 complaints about driving accident and Zolpidem intake, for many years, there was a spike in 2007, when the label was changed and more people complained. But a connection between the report and the drug was not easy to make, as they did not remembered the time of pill intake as they were drinking.

Until the time when agency performed controlled test of Inetrmezzo to get driving simulation, approved in 2011 for walking in mid of night, then they were aware of the risk. The driving simulation was then associated with the quantity of Zolpidem in the blood, if there was 50nanograms/milliliter that can cause accidents, as confirmed by Dr. Ellis Unger, Agency officer, Center for Drug Evaluation and Research.

Dr. Unger also said that all sleeping pills manufacturers have to perform driving trials; however a spokesperson said that it is not necessary. Dr. Unger also added that it is a big problem and he is not sure why this decision was taken so late.

For the immediate release products such as Zolpimist, Edluar and Ambien, the normal dosage needs to be lessened to5mg from 10mg. For extended release it has to be lessened to 6.25mg from 12.5mg. Most of Zolpidem containing drugs are now generic.

For men the label should state that lower dose should be considered.

Patient’s prescribed higher dose should take them but agency said that they should speak with their doctors about lowering them as doctors can again switch to higher one of the lower is not working, as said by Dr. Unger lower doses are available they are used in older patients.

The manufacturer of Ambien CR and Ambien is Sanofi, they said that, it is always recommended to check with your doctor for dosage and also to know what it is; the label has important information. Company is supporting the clinical trials that are required for efficacy and safety.

Dr. Unger said that there are reports that Zolpidem causes sleep walk, hence the lowering of the dose may lower this, though it is not as strong as drowsiness in the morning. One of the patients of Dr. Carlat was gaining weight as was not able to remember the midnight trips that he use to do to the kitchen.

Dr. Daniel Kripke, Professor, Psychiatry, University of California, he agreed to the move with happiness but at the same time he wants the agency to look for other side effects as well.

He said it is a good move and in a right way. He also said that sleeping pills increase the sleep by 20 mins but can hamper the next day’s performance.

Agency’s critic said that on the Intermezzo label, there is a clear warning for women; hence agency was well aware about the problem.

However Thomas Roth, Director, Sleep center, Henry Ford Hospital, Detroit, also sleeping pills makers’ consultant, said that agency was concerned about the sleepy driving, but now they care more, the lowered dose will surely help in this.

Agency said that every patient will have different dose and they will be prescribed accordingly, however the dosage will be as lowest as possible.

Dr. Daniel J. Buysse, Professor, Psychiatry, University of Pittsburgh School of Medicine, said that he has started telling the patient to take half dose if required by telling to cut the tablet half.

Also said that we will have to be more attentive in this and will not have big effect in what he has done.

FDA to take final call on smokeless tobacco products

Dissolvable Tobacco products are restricted for kids below 18 years. Tobacco products may have smell like candy bar but they are not for kids, the United States Food and Drug Department highlighted in a conference this week.

Dissolvable tobacco products are available in market, such as mint flavored, stick and strips of fumeless tobacco. These products are relief to those, to whom smoking is restricted. The desire for nicotine to satisfy ones need, Dissolvable tobacco products are made.

Star Scientific Inc., is promoting two new dissolvable tobacco product, namely Ariva and Stonewall. Even R.J. Reynolds Tobacco Co. is going to promote their Camel Strips,Camel Orbs, and Camel Sticks in 2 towns. Health Supporters are fretful about these Tobacco products, children and teens are more likely to it. The nicotine in product is the reason for addiction.

A pediatrician at Massachusetts General Hospital in Boston, Dr. Jonathan Winickoff commented the products look like a candy although, the nicotine levels in it is the cause of addiction in adolescents and adults.

The smokeless tobacco dissolvable products are second very popular cause of nicotine toxin substance in broods. A study showed in Journal Pediatrics, April 2010.

Winickoff also said that if youth is previously consuming cigarettes then there is not a single question arises that youth is not indulging Dissolvable tobacco products. Parents must bother for their kids and prevent then from consuming those nicotine products. Dissolvable products smell like candy or in mint taste it doesn’t mean that they are harmless, they are equally harmful as cigarettes are.

Headaches, diarrhea, vomiting, nausea are the signs of nicotine symptoms, whereas dangerous nicotine toxic substances leads in heart palpitations, involuntary twitching, muscle paralysis and may even cause deaths.

When experimented, 1 milligram of nicotine given to toddler, diarrhea and vomiting takes place. It is found that Camel Dissolvable Tobacco Products contain 0.6mg to 3.1 mg of nicotine, liable to products. A normal typical cigarette contains 1mg of nicotine.

Orbs manufacturer R.J Reynolds commented that major steps are taking place as to cure unintended breakdown of Camel Dissolvable Tobacco Products in youth, and providing instructions to poison management centers regarding probable consequences of unintended consumption.

Tobacco Products must be out of reach from children below and 18 years, is the warning line written on products.

Food and Drug Administration department has all the power to put control over these products, according to 2009 Family Smoking Prevention and Tobacco Control Act. Winickoff stated that FDA will take major steps in controlling these tobacco products among youth.

FDA has approved 1st biologic medication for children with ulcerative colitis (UC)

The U.S. Food and Drug Administration (FDA) has approved Remicade (infliximab) to moderately treat the vigorous ulcerative colitis (UC) in patients younger than six years, and have a insufficient reaction to the unconventional therapy.

There are around 1.4 millions of Americans adults and kids living with inflammatory bowel disease (IBD). Its is said that they are split between ulcerative colitis (UC) and Crohn’s disease. Predictably there are 150000 children below the age of 17 who are living with the symptoms of inflammatory bowel disease (IBD).

Ulcerative colitis (UC) is a kind of inflammatory bowel disease (IBD) that distress the inside layer of the large intestine (colon) and rectum and the cause of ulcerative colitis (UC) is still unidentified. Ulcerative colitis (UC) can affect people for all age group, even thought it is high to be affect at the age of 15-30.

Earlier there was no approved therapy for ulcerative colitis (UC) which is a distressing disease and had an insufficient respond to this conventional therapy. Due to this approval, Remicade (infliximab) represents an unconventional treatment in treating children suffering from inflammatory bowel disease (IBD).

Remicade (infliximab) permit is supported by the proof from a sufficient and well controlled study in young ones suffering from ulcerative colitis (UC). Treating ulcerative colitis (UC) with infliximab, strength 5 mg/kg has clinically responded to the patients in 8 weeks and established a safe profile, with a clinical examination carried out in adults as well.

In small kids all the vaccines should be up to date prior to initiating the medication with infliximab and should avoid receive vaccination while treating with infliximab. Few of the most frequent side effects of infliximab is worsening of ulcerative colitis (UC), respiratory infections, and headache.

FDA Accord with Drug makers Raises User Fees 6% to Renew Law

Drug manufacturers Pfizer Inc. and Eli Lilly & Co. have agreed with regulators on increasing 6% fees, as a part of their reauthorizing drug-approval process through financial year 2017. This accord has disclosed in parts on September 1st. The law will expire on Sept.30, 2012, so it must be approved before the given date.

The increased fees are likely to put in $40.4 million, revenue for the financial year 2012 and bringing the revenue toward $712.8 million by the year 2013.

The accord should permit more time to access for new safe and effective medicine. According to FDA, the agreement includes extra review time for the organization to fit in the extra meetings, by extending the for reviews after submitting applications to 8-months from 6-months, and 10-months to 12-months.

The FDA and the manufactures have agreed to set up the advisory panels and giving companies the time to collect the required data, in accordance to the agreement.

Agreement will also include a 3rd party review; weather FDA is meeting all the drug-evaluating goals, according to the agreement. In 2007, user fees were reauthorized; Congress gave FDA new responsibilities, which grounds the organization to slow its evaluating process.

The agreement will also help to bring back Food and Drug Administration's review performance.

New York-based Eli Lilly and Pfizer have been discussing with the Food and Drug Administration for a user-fee renewal process ever since July 2010. Medical-device Company New Brunswick based Johnson & Johnson is in different talks on fees that they pay the agency for product reviews. Device industry discarded the agency's proposal for paying more than double fees.

Senators Seek Change in FDA's Interest Conflict Rule

A vital amendment is on way. US senators are about to bring change in rule for advisers involve in reviewing new drug approvals. This is because there were lots of cases when FDA could not find experts because of conflicts of interest.

Lawmakers want FDA to loose regulations according to which advisers are not allowed to review new drug application if the respective person is financially associated with manufacturers. Current regulation makes it hard to find experts to be hired on review panel.

FDA is largely funded by fees taken from manufacturer of drug who are seeking FDA approval to make drug available in market. Hence, FDA's funding bill is a way to make major changes in the way FDA work.

Issue was raised by Mike Enzi and Al Franken, senators from Republican and Democratic party respectively.

FDA has to postpone meeting of drug-review committee while finding adviser without any conflicts. Expert doctors are already recruited by manufacturers as consultant and rule prevents FDA to hire same doctor in advisory panel.

FDA in May reported 23% vacant position in advisory panel.

Although FDA is free to avoid recommendations from advisor, it usually follows.

In the wake of Vioxx pain drug controversy, FDA made regulatory changes which restricted appointment of a person with financial ties fearing impact on one's view.

There are currently 10 panelists in FDA advisory panel who were also consulted by drug manufacturers. 9 panelists recommended bringing a drug in market which was called back in 2004.

Hamburg, FDA Commissioner, is also in favour of relaxed rule.